Active, not recruiting
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
- Conditions
- Connective Tissue Diseases, Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease, +7 more
- Locations
-
- Mayo Clinic - Scottsdale ( Site 4014) Phoenix, Arizona, United States
- Pacific Arthritis Care Center ( Site 4008) Los Angeles, California, United States
- Cedars Sinai Medical Center ( Site 4010) Los Angeles, California, United States
- UCLA School of Medicine ( Site 4006) Los Angeles, California, United States